A review of COVID-19 vaccines and major considerations for diabetic patients

Biotechnol Appl Biochem. 2022 Feb;69(1):30-40. doi: 10.1002/bab.2076. Epub 2021 Jan 21.

Abstract

The necessity and impact of SARS-CoV2 on the world's health have led to developing and producing practical and useful vaccines for this deadly respiratory virus. Since April 2020, a vaccine for the virus has been developed. Given that comorbidities such as diabetes, hypertension, and cardiovascular disease are more prone to viruses and the risk of infection, vaccines should be designed to protect against high-risk respiratory illnesses. Including SARS, MERS, influenza, and the SARS-CoV-2 provide a safe immune response. Here, we review the information and studies that have been done to help develop strategies and perspectives for producing a safe and ideal vaccine to prevent COVID-19 in normal people, especially at high-risk groups such as diabetes patients.

Keywords: COVID-19; Diabetes; SARS-CoV-2; Vaccine.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Diabetes Mellitus*
  • Humans
  • RNA, Viral
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • RNA, Viral